BLAINJECTIONINJECTABLE
Approved
Nov 2018
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
3/8 — Basic
Drug data last refreshed 2h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
UDENYCA (pegfilgrastim-cbqv) is a biosimilar granulocyte colony-stimulating factor (G-CSF) approved via Biologics License Application on November 2, 2018. It is indicated to reduce the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs. The drug works by stimulating the proliferation and differentiation of neutrophil precursor cells.
$8MPart D
PeakAt peak lifecycle with modest Part D spending of $8M and 1,535 claims in 2023, suggesting a mature biosimilar in a competitive segment with smaller commercial footprint than reference biologic.
Mechanism of Action
Pharmacologic Class:
Leukocyte Growth Factor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
An Analysis to Estimate Febrile Neutropenia (FN) in Patients Receiving Udenyca
Started Aug 2020
200 enrolled
Febrile NeutropeniaNon-myeloid Malignancy
Career Relevance
UDENYCA roles are primarily commercial-facing, centered on payer negotiations, formulary placement, and market share defense in a crowded biosimilar segment. Career progression on this product emphasizes managed care expertise, contracting skills, and competitive positioning rather than clinical or development innovation.
Account Executive
Worked on UDENYCA at Coherus Biosciences Inc? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.